AngioDynamics, Inc. (ANGO)
USD 8.93
(-3.56%)
USD 8.93
(-3.56%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -97.71 Million USD | -900.55% |
| 2023 | -19.23 Million USD | -1.19% |
| 2022 | -19 Million USD | -27.82% |
| 2021 | -14.87 Million USD | -4.96% |
| 2020 | -14.16 Million USD | -166.09% |
| 2019 | 21.43 Million USD | 103.02% |
| 2018 | 10.55 Million USD | -29.46% |
| 2017 | 14.96 Million USD | 2192.04% |
| 2016 | 653 Thousand USD | 165.69% |
| 2015 | -994 Thousand USD | -107.39% |
| 2014 | 13.44 Million USD | 89.57% |
| 2013 | 7.09 Million USD | 339.5% |
| 2012 | -2.96 Million USD | -124.47% |
| 2011 | 12.1 Million USD | -41.99% |
| 2010 | 20.87 Million USD | 29.6% |
| 2009 | 16.1 Million USD | -0.81% |
| 2008 | 16.23 Million USD | 244.64% |
| 2007 | -11.22 Million USD | -208.92% |
| 2006 | 10.3 Million USD | 33.38% |
| 2005 | 7.72 Million USD | 50.83% |
| 2004 | 5.12 Million USD | 58.21% |
| 2003 | 3.23 Million USD | 35.59% |
| 2002 | 2.38 Million USD | 923.45% |
| 2001 | -290 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 35.03 Million USD | 1471.04% |
| 2024 Q3 | -11.59 Million USD | 11.6% |
| 2024 FY | -33.84 Million USD | -75.97% |
| 2024 Q4 | -5.8 Million USD | 49.95% |
| 2024 Q2 | -13.12 Million USD | -137.45% |
| 2023 Q1 | -7.5 Million USD | -73.06% |
| 2023 Q2 | -3.66 Million USD | 51.23% |
| 2023 Q3 | -5.33 Million USD | -45.6% |
| 2023 Q4 | -2.55 Million USD | 52.08% |
| 2023 FY | -19.23 Million USD | -1.19% |
| 2022 FY | -19 Million USD | -27.82% |
| 2022 Q4 | -4.33 Million USD | -43.49% |
| 2022 Q3 | -3.02 Million USD | 65.16% |
| 2022 Q2 | -8.67 Million USD | -7.15% |
| 2022 Q1 | -8.1 Million USD | 62.48% |
| 2021 Q4 | -21.58 Million USD | -477.5% |
| 2021 Q3 | -3.73 Million USD | 22.7% |
| 2021 FY | -14.87 Million USD | -4.96% |
| 2021 Q2 | -4.83 Million USD | 5.58% |
| 2021 Q1 | -5.12 Million USD | 96.71% |
| 2020 FY | -14.16 Million USD | -166.09% |
| 2020 Q4 | -155.61 Million USD | -2395.37% |
| 2020 Q3 | -6.23 Million USD | -82.18% |
| 2020 Q2 | -3.42 Million USD | -313.41% |
| 2020 Q1 | -828 Thousand USD | -107.47% |
| 2019 Q2 | 3.98 Million USD | 1121.17% |
| 2019 FY | 21.43 Million USD | 103.02% |
| 2019 Q1 | 326 Thousand USD | -92.65% |
| 2019 Q4 | 11.08 Million USD | 297.88% |
| 2019 Q3 | 2.78 Million USD | -29.99% |
| 2018 Q2 | 1.12 Million USD | 702.14% |
| 2018 Q1 | 140 Thousand USD | 101.5% |
| 2018 FY | 10.55 Million USD | -29.46% |
| 2018 Q4 | 4.43 Million USD | -8.74% |
| 2018 Q3 | 4.86 Million USD | 332.77% |
| 2017 FY | 14.96 Million USD | 2192.04% |
| 2017 Q2 | 15.58 Million USD | 336.39% |
| 2017 Q3 | 5.14 Million USD | -67.03% |
| 2017 Q4 | -9.33 Million USD | -281.58% |
| 2017 Q1 | 3.57 Million USD | 267.7% |
| 2016 Q3 | 2.68 Million USD | 104.02% |
| 2016 Q1 | 1.07 Million USD | -20.15% |
| 2016 FY | 653 Thousand USD | 165.69% |
| 2016 Q2 | 1.31 Million USD | 23.08% |
| 2016 Q4 | -2.13 Million USD | -179.27% |
| 2015 FY | -994 Thousand USD | -107.39% |
| 2015 Q1 | 3.57 Million USD | -4.59% |
| 2015 Q4 | 1.34 Million USD | 113.2% |
| 2015 Q3 | -10.15 Million USD | -321.88% |
| 2015 Q2 | 4.57 Million USD | 27.9% |
| 2014 Q3 | 7.56 Million USD | 380.88% |
| 2014 Q1 | 1.28 Million USD | 4.55% |
| 2014 Q4 | 3.74 Million USD | -50.47% |
| 2014 Q2 | 1.57 Million USD | 22.3% |
| 2014 FY | 13.44 Million USD | 89.57% |
| 2013 Q1 | 684 Thousand USD | 109.99% |
| 2013 FY | 7.09 Million USD | 339.5% |
| 2013 Q4 | 1.23 Million USD | 2022.41% |
| 2013 Q3 | 58 Thousand USD | -98.87% |
| 2013 Q2 | 5.12 Million USD | 648.83% |
| 2012 Q1 | 2.71 Million USD | 234.57% |
| 2012 FY | -2.96 Million USD | -124.47% |
| 2012 Q4 | -6.84 Million USD | -148.35% |
| 2012 Q3 | -2.75 Million USD | -170.22% |
| 2012 Q2 | 3.92 Million USD | 44.5% |
| 2011 Q2 | 5.39 Million USD | 55.04% |
| 2011 FY | 12.1 Million USD | -41.99% |
| 2011 Q4 | -2.01 Million USD | -138.47% |
| 2011 Q1 | 3.48 Million USD | -45.46% |
| 2011 Q3 | 5.24 Million USD | -2.76% |
| 2010 Q4 | 6.38 Million USD | 14.12% |
| 2010 FY | 20.87 Million USD | 29.6% |
| 2010 Q3 | 5.59 Million USD | 5.13% |
| 2010 Q1 | 3.57 Million USD | -24.93% |
| 2010 Q2 | 5.32 Million USD | 48.81% |
| 2009 FY | 16.1 Million USD | -0.81% |
| 2009 Q1 | 3.82 Million USD | 1090.65% |
| 2009 Q4 | 4.76 Million USD | 81.06% |
| 2009 Q3 | 2.63 Million USD | -46.22% |
| 2009 Q2 | 4.89 Million USD | 27.94% |
| 2008 Q2 | 4.79 Million USD | 36.04% |
| 2008 FY | 16.23 Million USD | 244.64% |
| 2008 Q3 | 7.6 Million USD | 58.73% |
| 2008 Q1 | 3.52 Million USD | -12.67% |
| 2008 Q4 | 321 Thousand USD | -95.78% |
| 2007 Q3 | -20.08 Million USD | -768.58% |
| 2007 FY | -11.22 Million USD | -208.92% |
| 2007 Q2 | 3 Million USD | 64.78% |
| 2007 Q4 | 4.03 Million USD | 120.08% |
| 2007 Q1 | 1.82 Million USD | -41.27% |
| 2006 Q2 | 2.39 Million USD | 25.34% |
| 2006 Q4 | 3.1 Million USD | 7.44% |
| 2006 Q3 | 2.88 Million USD | 20.43% |
| 2006 Q1 | 1.91 Million USD | -23.96% |
| 2006 FY | 10.3 Million USD | 33.38% |
| 2005 Q4 | 2.51 Million USD | 17.18% |
| 2005 FY | 7.72 Million USD | 50.83% |
| 2005 Q3 | 2.14 Million USD | 19.8% |
| 2005 Q1 | 1.27 Million USD | -33.72% |
| 2005 Q2 | 1.79 Million USD | 41.18% |
| 2004 Q3 | 1.06 Million USD | 0.0% |
| 2004 Q4 | 1.91 Million USD | 79.23% |
| 2004 FY | 5.12 Million USD | 58.21% |
| 2003 FY | 3.23 Million USD | 35.59% |
| 2003 Q4 | 1.04 Million USD | -84.59% |
| 2003 Q3 | 6.8 Million USD | 0.0% |
| 2002 FY | 2.38 Million USD | 923.45% |
| 2001 FY | -290 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | -69.449% |
| AtriCure, Inc. | -26.68 Million USD | -266.218% |
| Avinger, Inc. | -16.63 Million USD | -487.424% |
| Azenta, Inc. | -73.12 Million USD | -33.63% |
| BioLife Solutions, Inc. | -70.82 Million USD | -37.971% |
| The Cooper Companies, Inc. | 533.1 Million USD | 118.33% |
| Daxor Corporation | -177.07 Thousand USD | -55084.526% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | -546.625% |
| Femasys Inc. | -14.5 Million USD | -573.526% |
| GlucoTrack, Inc. | -7.1 Million USD | -1275.535% |
| Harvard Bioscience, Inc. | 1.89 Million USD | 5259.345% |
| Hologic, Inc. | 882.6 Million USD | 111.072% |
| ICU Medical, Inc. | 22.82 Million USD | 528.118% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 105.531% |
| KORU Medical Systems, Inc. | -10.26 Million USD | -851.492% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | 363.519% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -1316.092% |
| Innovative Eyewear, Inc. | -6.9 Million USD | -1316.092% |
| Masimo Corporation | 136.5 Million USD | 171.588% |
| Microbot Medical Inc. | -9.85 Million USD | -891.558% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | 765.884% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 178.84% |
| Nephros, Inc. | -1.59 Million USD | -6034.212% |
| NovoCure Limited | -232.87 Million USD | 58.038% |
| NEXGEL, Inc. | -3.47 Million USD | -2710.411% |
| NEXGEL, Inc. | -3.47 Million USD | -2710.411% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 4.945% |
| OraSure Technologies, Inc. | 54.07 Million USD | 280.695% |
| Pro-Dex, Inc. | 7.17 Million USD | 1462.303% |
| Pulse Biosciences, Inc. | -43.57 Million USD | -124.258% |
| Predictive Oncology Inc. | -13.92 Million USD | -601.93% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | -3486.86% |
| QuidelOrtho Corporation | 139.1 Million USD | 170.25% |
| Repligen Corporation | 54.57 Million USD | 279.049% |
| Sanara MedTech Inc. | -4.21 Million USD | -2218.255% |
| STAAR Surgical Company | 28.09 Million USD | 447.788% |
| Sharps Technology, Inc. | -10.12 Million USD | -864.959% |
| Utah Medical Products, Inc. | 16.77 Million USD | 682.452% |
| DENTSPLY SIRONA Inc. | -85 Million USD | -14.962% |
| Jin Medical International Ltd. | 2.86 Million USD | 3508.06% |